modelJ01DC13
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Cefbuperazone | |
| ATC code: | J01DC13 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 1000 | mg |
| volume of distribution: | 12 | L |
| clearance: | 4.5 | L/h |
| other parameters in model implementation | ||
Cefbuperazone is a second-generation cephalosporin antibiotic, structurally related to cefoperazone. It has a broad spectrum of activity against various Gram-positive and Gram-negative bacteria, and has primarily been used to treat respiratory, urinary, and biliary tract infections. Its use is largely limited to certain countries, mainly in East Asia, and is not widely approved or used in the United States or Europe today.
Pharmacokinetics
Estimated pharmacokinetic parameters for healthy adult individuals. No published clinical pharmacokinetic studies with detailed parameters are available in the scientific literature.
References
Liu, D, et al., & Ding, L (2016). Pharmacokinetic profile of cefbuperazone in healthy Chinese volunteers after single and multiple drip intravenous infusion by HPLC-MS/MS. Journal of pharmaceutical and biomedical analysis 129 28–33. DOI:10.1016/j.jpba.2016.06.029 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27394175
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)